These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 23892183)

  • 41. Escaping the pincer.
    Nat Rev Drug Discov; 2009 Dec; 8(12):915. PubMed ID: 19967796
    [No Abstract]   [Full Text] [Related]  

  • 42. Outsourcing chemical synthesis in the drug discovery process.
    Festel G
    Drug Discov Today; 2011 Mar; 16(5-6):237-43. PubMed ID: 21262378
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Does size matter in R&D productivity? If not, what does?
    Ringel M; Tollman P; Hersch G; Schulze U
    Nat Rev Drug Discov; 2013 Dec; 12(12):901-2. PubMed ID: 24136396
    [No Abstract]   [Full Text] [Related]  

  • 44. Patient-centered drug discovery as the means to improved R&D productivity.
    Raoof AA; Aerssens J
    Drug Discov Today; 2015 Sep; 20(9):1044-8. PubMed ID: 25908579
    [No Abstract]   [Full Text] [Related]  

  • 45. Powered by Open Innovation: Opportunities and Challenges in the Pharma Sector.
    Martinez-Grau MA; Alvim-Gaston M
    Pharmaceut Med; 2019 Jun; 33(3):193-198. PubMed ID: 31933287
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical research opportunities: what you need to know for your practice.
    Glatz NF; Gregory SJ; Law BT; Riner RN
    Heart Dis; 2000; 2(4):287-92. PubMed ID: 11728271
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Can open-source R&D reinvigorate drug research?
    Munos B
    Nat Rev Drug Discov; 2006 Sep; 5(9):723-9. PubMed ID: 16915233
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Opinion: The future of pharmaceutical R&D: somewhere between open and reverse innovation?
    Talaga P
    Future Med Chem; 2010 Sep; 2(9):1399-403. PubMed ID: 21426134
    [No Abstract]   [Full Text] [Related]  

  • 49. Biopharma business models in Canada.
    March-Chordà I; Yagüe-Perales RM
    Drug Discov Today; 2011 Aug; 16(15-16):654-8. PubMed ID: 21708279
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of mergers and acquisitions on drug discovery: perspective from a case study of a Japanese pharmaceutical company.
    Shibayama S; Tanikawa K; Fujimoto R; Kimura H
    Drug Discov Today; 2008 Jan; 13(1-2):86-93. PubMed ID: 18190869
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drug discovery: are productivity metrics inhibiting motivation and creativity?
    Ullman F; Boutellier R
    Drug Discov Today; 2008 Nov; 13(21-22):997-1001. PubMed ID: 18652910
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Open-access public-private partnerships to enable drug discovery--new approaches.
    Müller S; Weigelt J
    IDrugs; 2010 Mar; 13(3):175-80. PubMed ID: 20191434
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Concerns raised over declining antiinfectives R&D.
    Fox JL
    Nat Biotechnol; 2003 Nov; 21(11):1255-6. PubMed ID: 14595340
    [No Abstract]   [Full Text] [Related]  

  • 54. Discovery of innovative therapeutics: today's realities and tomorrow's vision. 2. Pharma's challenges and their commitment to innovation.
    Abou-Gharbia M; Childers WE
    J Med Chem; 2014 Jul; 57(13):5525-53. PubMed ID: 24428137
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Keynote review: Is declining innovation in the pharmaceutical industry a myth?
    Schmid EF; Smith DA
    Drug Discov Today; 2005 Aug; 10(15):1031-9. PubMed ID: 16055019
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Do large mergers increase or decrease the productivity of pharmaceutical R&D?
    Ringel MS; Choy MK
    Drug Discov Today; 2017 Dec; 22(12):1749-1753. PubMed ID: 28646641
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Health research and innovation: Can we optimize the interface between startups/pharmaceutical companies and academic health care institutions or not?
    Dhainaut JF; Blin O; Herry F; ; Benito S; Bilbault P; Cauterman M; Favrel-Feuillade F; Fazi-Leblanc S; Germain C; Goehrs C; Grosskopf C; Labarthe B; Lechat P; Malciu C; Marquet P; Miceli-Richard C; Peyret O; Rattenbach R; de Saint-Exupéry E
    Therapie; 2020; 75(1):113-123. PubMed ID: 31948660
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gentris corporation.
    Crean J
    Pharmacogenomics; 2002 Jan; 3(1):148-50. PubMed ID: 11966411
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Driving external chemistry optimization via operations management principles.
    Bi FC; Frost HN; Ling X; Perry DA; Sakata SK; Bailey S; Fobian YM; Sloan L; Wood A
    Drug Discov Today; 2014 Mar; 19(3):289-94. PubMed ID: 23973340
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An audience with...Marc Cluzel.
    Cluzel M
    Nat Rev Drug Discov; 2010 Jan; 9(1):14. PubMed ID: 20043024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.